Literature DB >> 14668741

Aggressive surgery for metastatic liver neuroendocrine tumors.

Jeffrey A Norton1, Robert S Warren, Mary G Kelly, Marlene B Zuraek, Robert T Jensen.   

Abstract

BACKGROUND: Neuroendocrine tumors of the gastrointestinal tract (carcinoids, pancreatic endocrine tumors) have low malignant potential but can decrease survival rates if they spread to the liver (LNET).
METHODS: The records of 16 patients with LNET primarily from gastrointestinal carcinoids treated surgically were retrospectively reviewed.
RESULTS: There were 12 women and 4 men. Median age was 56 years (range 25 to 75). Thirteen (81%) had a carcinoid tumor and 5 had gastrinoma. Two patients with multiple endocrine neoplasia type 1 had both a gastric carcinoid and a jejunal gastrinoma. Eight patients (50%) had the carcinoid syndrome. Each patient had all identifiable LNET either resected or ablated. Ten patients had liver wedge resections, 1 right trisegmentectomy, 5 left hepatic lobectomies, and 2 radiofrequency ablations. Thirteen (81%) patients had concomitant bowel resections. Two patients had concomitant total gastrectomies to remove stomach primaries. The final patient had an extraintestinal pelvic primary or a liver primary. There were no operative deaths, and all 8 (100%) patients with the carcinoid syndrome had amelioration of symptoms. The 5-year actuarial survival rate was 82% with a median follow-up of 32 months.
CONCLUSIONS: This study demonstrates that liver and concomitant extrahepatic surgery can be performed safely in patients with liver metastases because of carcinoids or pancreatic endocrine tumors. It results in excellent long-term survival and amelioration of symptoms. Surgery should be the first-line therapy for patients with LNET.

Entities:  

Mesh:

Year:  2003        PMID: 14668741     DOI: 10.1016/j.surg.2003.07.025

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  71 in total

1.  Pancreatic neuroendocrine tumours: hypoenhancement on arterial phase computed tomography predicts biological aggressiveness.

Authors:  David J Worhunsky; Geoffrey W Krampitz; Peter D Poullos; Brendan C Visser; Pamela L Kunz; George A Fisher; Jeffrey A Norton; George A Poultsides
Journal:  HPB (Oxford)       Date:  2013-08-29       Impact factor: 3.647

2.  Aggressive surgery improves long-term survival in neuroendocrine pancreatic tumors: an institutional experience.

Authors:  Paulus G Schurr; Tim Strate; Kim Rese; Jussuf T Kaifi; Uta Reichelt; Susanne Petri; Helge Kleinhans; Emre F Yekebas; Jakob R Izbicki
Journal:  Ann Surg       Date:  2007-02       Impact factor: 12.969

3.  A phase II clinical trial of sunitinib following hepatic transarterial embolization for metastatic neuroendocrine tumors.

Authors:  J R Strosberg; J M Weber; J Choi; T L Campos; T L Valone; G Han; M J Schell; L K Kvols
Journal:  Ann Oncol       Date:  2012-02-08       Impact factor: 32.976

4.  Palliative management strategies of advanced gastrointestinal carcinoid neoplasms.

Authors:  Paola Sartori; Chiara Mussi; Carlo Angelini; Stefano Crippa; Roberto Caprotti; Franco Uggeri
Journal:  Langenbecks Arch Surg       Date:  2005-06-21       Impact factor: 3.445

Review 5.  Liver transplantation for metastatic neuroendocrine tumor: a case report and review of the literature.

Authors:  Wojciech C Blonski; K Rajender Reddy; Abraham Shaked; Evan Siegelman; David C Metz
Journal:  World J Gastroenterol       Date:  2005-12-28       Impact factor: 5.742

6.  Curative versus palliative surgical resection of liver metastases in patients with neuroendocrine tumors: a meta-analysis of observational studies.

Authors:  Stefano Bacchetti; Enrico Maria Pasqual; Serena Bertozzi; Ambrogio P Londero; Andrea Risaliti
Journal:  Gland Surg       Date:  2014-11

Review 7.  Advances in the treatment of neuroendocrine tumors.

Authors:  Matthew Kulke
Journal:  Curr Treat Options Oncol       Date:  2005-09

8.  PTCH 1 staining of pancreatic neuroendocrine tumor (PNET) samples from patients with and without multiple endocrine neoplasia (MEN-1) syndrome reveals a potential therapeutic target.

Authors:  Buddha Gurung; Xianxin Hua; Melissa Runske; Bonita Bennett; Virginia LiVolsi; Robert Roses; Douglas A Fraker; David C Metz
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

9.  Pancreatic neuroendocrine tumours.

Authors:  J Ruiz-Tovar; P Priego; E Martínez-Molina; V Morales; A Sanjuanbenito; E Lobo
Journal:  Clin Transl Oncol       Date:  2008-08       Impact factor: 3.405

10.  Is Multifocality an Indicator of Aggressive Behavior in Small Bowel Neuroendocrine Tumors?

Authors:  Allen B Choi; Jessica E Maxwell; Kendall J Keck; Andrew J Bellizzi; Joseph S Dillon; Thomas M OʼDorisio; James R Howe
Journal:  Pancreas       Date:  2017-10       Impact factor: 3.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.